Jose L. Lopez-Ribot to Microbial Sensitivity Tests
This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Microbial Sensitivity Tests.
Connection Strength
3.388
-
Pierce CG, Saville SP, Lopez-Ribot JL. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis. 2014 Apr; 70(3):423-31.
Score: 0.448
-
Pierce CG, Uppuluri P, Tummala S, Lopez-Ribot JL. A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. J Vis Exp. 2010 Oct 21; (44).
Score: 0.354
-
Ramage G, L?pez-Ribot JL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med. 2005; 118:71-9.
Score: 0.237
-
Ajetunmobi OH, Chaturvedi AK, Badali H, Vaccaro A, Najvar L, Wormley FL, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. APMIS. 2023 Nov; 131(11):613-625.
Score: 0.213
-
Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods Mol Biol. 2023; 2658:53-64.
Score: 0.206
-
Lara HH, Ixtepan-Turrent L, Jose Yacaman M, Lopez-Ribot J. Inhibition of Candida auris Biofilm Formation on Medical and Environmental Surfaces by Silver Nanoparticles. ACS Appl Mater Interfaces. 2020 May 13; 12(19):21183-21191.
Score: 0.168
-
Vazquez-Mu?oz R, Arellano-Jimenez MJ, Lopez FD, Lopez-Ribot JL. Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities. BMC Res Notes. 2019 Nov 27; 12(1):773.
Score: 0.166
-
Vila T, Lopez-Ribot JL. Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother. 2017 01; 61(1).
Score: 0.136
-
Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence. 2017 02 17; 8(2):138-142.
Score: 0.131
-
Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother. 2015 Dec; 59(12):7611-20.
Score: 0.125
-
Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother. 2014; 58(2):1183-6.
Score: 0.109
-
Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnol Bioeng. 2014 Feb; 111(2):418-24.
Score: 0.109
-
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. J Vis Exp. 2012 Jul 18; (65):e3845.
Score: 0.100
-
Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012 Jan; 55(1):80-5.
Score: 0.093
-
Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011 Jul; 55(7):3591-3.
Score: 0.092
-
Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol. 2009 Dec; 47(12):4078-83.
Score: 0.082
-
Uppuluri P, Chaturvedi AK, Lopez-Ribot JL. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia. 2009 Sep; 168(3):101-9.
Score: 0.080
-
Li X, Brown N, Chau AS, L?pez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan; 53(1):74-80.
Score: 0.055
-
Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, L?pez-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002 Nov; 46(11):3591-6.
Score: 0.051
-
Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
Score: 0.049
-
Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001 Sep; 45(9):2475-9.
Score: 0.047
-
Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab. 2001 Aug; 20(7):42-4.
Score: 0.047
-
Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999 Jul; 43(7):1621-30.
Score: 0.040
-
Lara HH, Guisbiers G, Mendoza J, Mimun LC, Vincent BA, Lopez-Ribot JL, Nash KL. Synergistic antifungal effect of chitosan-stabilized selenium nanoparticles synthesized by pulsed laser ablation in liquids against Candida albicans biofilms. Int J Nanomedicine. 2018; 13:2697-2708.
Score: 0.037
-
Torres NS, Abercrombie JJ, Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK, Leung KP. Screening a Commercial Library of Pharmacologically Active Small Molecules against Staphylococcus aureus Biofilms. Antimicrob Agents Chemother. 2016 10; 60(10):5663-72.
Score: 0.033
-
Actis L, Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK, Ong JL. Effect of silver nanoparticle geometry on methicillin susceptible and resistant Staphylococcus aureus, and osteoblast viability. J Mater Sci Mater Med. 2015 Jul; 26(7):215.
Score: 0.031
-
Siles SA, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother. 2013 Aug; 57(8):3681-7.
Score: 0.026
-
Ramage G, Tomsett K, Wickes BL, L?pez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul; 98(1):53-9.
Score: 0.014
-
Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
Score: 0.014
-
Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
Score: 0.013
-
Ramage G, VandeWalle K, L?pez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett. 2002 Aug 27; 214(1):95-100.
Score: 0.013
-
Perea S, L?pez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Jun; 46(6):1695-703.
Score: 0.012
-
Mart?nez M, L?pez-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002 Mar; 49(3):515-24.
Score: 0.012
-
Viudes A, Cant?n E, Pem?n J, L?pez-Ribot JL, Gobernado M. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Rev Esp Quimioter. 2002 Mar; 15(1):32-42.
Score: 0.012
-
Perea S, L?pez-Ribot JL, Kirkpatrick WR, McAtee RK, Santill?n RA, Mart?nez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001 Oct; 45(10):2676-84.
Score: 0.012
-
Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Patterson TF. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol. 1999 Dec; 37(12):3896-900.
Score: 0.010
-
Kirkpatrick WR, Revankar SG, Mcatee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol. 1998 Oct; 36(10):3007-12.
Score: 0.010